FemHealth Ventures

Cercle advances women's healthcare by unlocking access to insights. Cercle’s platform, the Cercle Biomedical Graph™, transforms healthcare data at scale into real-time, high-quality insights that women's healthcare providers use to run more efficient businesses and provide personalized care.

Reunion Neuroscience is a clinical-stage pharmaceutical company focused on developing therapeutic solutions for underserved mental health conditions. Its lead asset, RE104, is a proprietary psychedelic compound being developed as a potential fast-acting and durable antidepressant for patients suffering from postpartum depression and other mental health conditions.

AOA, based in Boston, New York, and London, is a female-led company focused on developing innovative cancer diagnostics specifically for women's health. The company is dedicated to creating the first accurate early-stage liquid biopsy test for ovarian cancer, which aims to enhance clinical practices, reduce patient mortality, and offer cost savings for healthcare payers. Utilizing an artificial intelligence-enabled platform, AOA's technology analyzes tumor marker gangliosides to facilitate the early detection of ovarian cancer. This approach not only helps healthcare providers implement more effective treatment strategies but also ensures that patients can access life-saving treatments sooner and at a more affordable cost.

Rejoni, Inc. is a medical device company based in Bedford, Massachusetts, founded in 2020. It specializes in developing and commercializing innovative solutions aimed at enhancing the outcomes of gynecological surgical procedures. The company focuses on preventing scar formation after intrauterine interventions, addressing both acute and chronic risks associated with such procedures. By utilizing biomaterials, Rejoni creates gynecological products that prioritize women's health, enabling patients to achieve their desired quality of life both now and in the future.

Fogarty Innovation is a nonprofit organization based in Mountain View, California, focused on advancing medical innovation to enhance human health. Founded in 2007, the organization supports promising innovators and researchers by transforming their creative ideas into practical solutions that improve patient care. It operates as an incubator, providing essential funding, mentorship, and research tools to facilitate the development of medical concepts from inception to application. Fogarty Innovation offers two key programs: one aimed at fostering innovation for startups and another dedicated to educating the next generation of inventors. Through these initiatives, Fogarty Innovation coordinates access to vital intellectual, physical, and financial resources to drive medical advancements.

Raydiant Oximetry is a medical device company developing a non-invasive fetal monitoring device that measures fetal oxygen levels to improve outcomes for mothers and babies during childbirth and to reduce unnecessary cesarean sections. Founded in 2015 and based in California, the company aims to provide low-cost, real-time monitoring of fetal oxygenation during labor, enabling clinicians to assess fetal well-being and minimize intervention.

Nymbl Science is focused on enhancing balance and reducing falls among older adults through a scientifically validated digital training program. The company leverages medical science and mobile technology to offer a unique application that combines physical and cognitive training. Users engage in dual-tasking exercises that promote reflexive balance, using just a smartphone for approximately 10 minutes a day. This approach not only helps users measure and track their health care status but also empowers them to improve their balance, thereby boosting confidence and enhancing overall quality of life. Nymbl Science aims to prevent one million falls, ultimately allowing older adults to maintain their independence and enjoyment of life.

BioAesthetics develops tissue-engineered nipple-areolar complex grafts to support breast reconstruction after mastectomy. The graft is designed as a scaffold for the patient's own cells to populate and regenerate the nipple and areola during reconstruction, aiming to improve cosmetic and reconstructive outcomes. The company originated as a Tulane University spin-out and was founded in 2015.

Trefoil Therapeutics is a biotechnology company dedicated to developing innovative therapies for endothelial cell-mediated diseases, particularly those affecting the cornea. Utilizing its proprietary engineered fibroblast growth factor-1 technology platform, Trefoil aims to create first-in-class regenerative pharmacologic treatments for conditions such as Fuchs dystrophy and other serious corneal diseases that can lead to preventable blindness. The company is currently focused on a topical eye drop formulation known as TTHX1114, designed to treat ulcerative conditions on the cornea's surface, which can result in corneal scarring and significant vision loss. With a management team boasting over 100 years of combined experience in pharmaceutical development and commercialization, Trefoil strives to enhance human health through protein-engineered drug therapies. As an early-stage company, it has received recognition from the biopharmaceutical funding community for its innovative business approach.